MT760LW - Souris RAPOO - Notice d'utilisation et mode d'emploi gratuit

Type de produit	Souris sans fil
Marque	Rapoo
Modèle	MT760LW
Connectivité	2,4 GHz et Bluetooth
Capteur	Optique haute précision
Résolution	800/1200/1600/2400/3200 DPI
Nombre de boutons	6 (clic gauche, droit, molette, DPI, avancer, reculer)
Alimentation	Batterie lithium rechargeable 500 mAh
Autonomie	Jusqu'à 25 jours (usage normal)
Recharge	Port USB-C
Dimensions (L x l x H)	125 x 67 x 38 mm
Poids	95 g (avec batterie)
Compatibilité	Windows, macOS, Linux, Chrome OS
Molette	Molette de défilement 4D (haut/bas, gauche/droite)
Matériau	Plastique ABS avec revêtement soft-touch
Entretien et nettoyage	Nettoyer avec un chiffon doux et sec. Ne pas utiliser de solvants.
Sécurité	Utiliser uniquement un chargeur adapté. Ne pas exposer à l'eau.
Pièces détachées et réparabilité	Batterie remplaçable par un professionnel. Autres pièces non disponibles.
Garantie	2 ans
Contenu de la boîte	Souris, récepteur USB, câble USB-C, guide de démarrage rapide

FOIRE AUX QUESTIONS - MT760LW RAPOO

Comment connecter la souris MT760LW à mon ordinateur ?

Vous pouvez connecter la souris via le récepteur USB 2,4 GHz (insérez-le dans un port USB) ou via Bluetooth (activez le Bluetooth sur votre appareil, appuyez sur le bouton de couplage sous la souris pendant 3 secondes, puis sélectionnez 'Rapoo MT760' dans la liste des périphériques).

Comment recharger la batterie de la souris ?

Branchez le câble USB-C fourni à la souris et à un port USB de votre ordinateur ou à un chargeur mural (5V/1A). Le voyant rouge indique la charge, il s'éteint une fois complètement chargée.

Quelle est l'autonomie de la batterie ?

L'autonomie peut atteindre jusqu'à 25 jours en utilisation standard (8 heures par jour). Elle varie en fonction de la fréquence d'utilisation et du niveau de luminosité du rétroéclairage (si présent).

Comment ajuster la sensibilité (DPI) de la souris ?

Appuyez sur le bouton DPI situé en haut de la souris pour basculer entre les niveaux prédéfinis : 800, 1200, 1600, 2400, 3200 DPI. Le voyant clignote pour indiquer le niveau actuel.

La souris est-elle compatible avec macOS ?

Oui, la souris fonctionne avec Windows, macOS, Linux et Chrome OS. Aucun pilote spécifique n'est requis pour les fonctions de base.

Que faire si la souris ne s'allume pas ?

Vérifiez que la batterie est chargée. Branchez-la via USB-C pendant au moins 30 minutes. Si le problème persiste, essayez de réinitialiser la souris en maintenant les boutons gauche, droit et molette enfoncés pendant 5 secondes.

Comment nettoyer la souris ?

Utilisez un chiffon doux et sec pour nettoyer la surface. Pour les zones difficiles, vous pouvez humidifier légèrement le chiffon avec de l'eau. N'utilisez pas de produits chimiques ou abrasifs.

La molette ne défile-t-elle pas correctement ?

Assurez-vous qu'il n'y a pas de saleté accumulée. Nettoyez délicatement autour de la molette avec un coton-tige sec. Si le problème persiste, contactez le support technique.

Puis-je utiliser la souris pendant la charge ?

Oui, vous pouvez utiliser la souris en mode filaire lorsqu'elle est branchée via USB-C. Cela permet également de continuer à travailler si la batterie est faible.

Où puis-je trouver plus d'informations ou télécharger des pilotes ?

Visitez le site officiel de Rapoo (www.rapoo.com) dans la section support. Vous y trouverez les manuels, les logiciels de personnalisation des boutons et les mises à jour de firmware.

MODE D'EMPLOI MT760LW RAPOO

5605-05000-222

版本	制图人	日期	备注

53mm rapoo Quick Start Guide New York Guide: 100mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm WM1 New York Guide: 100mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200 mm New York Guide: 100mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200m New York Guide: 100mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm New York Guide: 100mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 200mm x 201.4 New York Guide: 100mm x 201.4 New York Guide: 116.4 New York Guide: 116.4 New York Guide: 116.4 New York Guide: 116.4 New York Guide: 116.4 New York Guide: 116.4 New York Guide: 116.4 New York Guide: 116.4 New York Guide: 116.4 New York Guide: 116. New York Guide: 116. New York Guide: 116. New York Guide: 116. New York Guide: 116. New York Guide: 116. New York Guide: 116. New York Guide: 116. New York Guide: 116. New York Guide: 116. New York Guide: 116. New York Guide: 116. N/A New York Guide: Product (8x7), Product (8x8), Product (8x9), Product (8x14), Product (8x15), Product (8x16), Product (8x17), Product (8x18), Product (8x19), Product (8x24), Product (8x25), Product (8x26), Product (8x27), Product (8x28), Product (8x35), Product (8x36), Product (8x37), Product (8x38), Product (8x39), Product (8x45), Product (8x46), Product (8x47), Product (8x48), Product (8x49), Product (8x55), Product (8x56), Product (8x57), Product (8x58), Product (8x59), Product (8x65), Product (8x66), Product (8x67), Product (8x68), Product (8x69), Product (8x75), Product (8x76), Product (8x77), Product (8x78), Product (8x79), Product (8x85), Product (8x86), Product (8x87), Product (8x88), Product (8x89), Product (8x95), Product (8x96), Product (8x97), Product (8x98), Product (8x99), Product (8x99). Legal & Compliance Information Product Window Charging Module Model WM1 Mandate Rapoo Europe B.V. Přírskomán West 27, 2995 PC Bototopyk www.rapoo.com www.rapoo.com UK Authorité Responsative Product Model Prosci(PLK) L&L Rorhombartov Av. London MUNBOW, United Kingdom Safety instruction: Schänebelücksliche / Carz anlagen de davon und sonstige Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Anlagen des Rechnungen und Angragen des Rechnungen und Angragen des Rechnungen und Angragen des Rechnungen und Angragen des Rechnungen und Angragen des Rechnungen und Angragen des Rechnungen und Angragen des Rechnungen und Angragen des Rechnungen und Angragen des Rechnungen und Angragen des Rechnungen und Angragen des Rechnungen und Angragen des Rechnungen und Angragen des Rechnungsmuchte N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A

3. Response to patients: Canadian women are very likely to be treated with diabetes treatment. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. 4. Patient screening: Canada is a primary treatment method for diabetes treatment. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. 5. Patient screening: Canada is a primary treatment method for diabetes treatment. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. 6. Patient screening: Canada is a primary treatment method for diabetes treatment. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. 7. Patient screening: Canada is a primary treatment method for diabetes treatment. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. 8. Patient screening: Canada is a primary treatment method for diabetes treatment. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. 9. Patient screening: Canada is a primary treatment method for diabetes treatment. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. 10. Patient screening: Canada is a primary treatment method for diabetes treatment. Patients are not able to follow the diagnosis of diabetes. Patients are not able to follow the diagnosis of diabetes. 11. Patient screening: Canada is a primary treatment method for diabetes treatment. Patients are not able to follow the diagnosis of diabetes. 12. Patient screening: Canada is a primary treatment method for diabetes treatment. 13. Patient screening: Canada is a primary treatment method for diabetes treatment. 14. Patient screening: Canada is a primary treatment method for diabetes treatment. 15. Patient screening: Canada is a primary treatment method for diabetes treatment. 16. Patient screening: Canada is a primary treatment method for diabetes treatment. 17. Patient screening: Canada is a primary treatment method for diabetes treatment. 18. Patient screening: Canada is a primary treatment method for diabetes treatment. 19. Patient screening: Canada is a primary treatment method for diabetes treatment. 20. Patient screening: Canada is a primary treatment method for diabetes treatment. 21. Patient screening: Canada is a primary treatment method for diabetes treatment. 22. Patient screening: Canada is a primary treatment method for diabetes treatment. 23. Patient screening: Canada is a primary treatment method for diabetes treatment. 24. Patient screening: Canada is a primary treatment method for diabetes treatment. 25. Patient screening: Canada is a primary treatment method for diabetes treatment. 26. Patient screening: Canada is a primary treatment method for diabetes treatment. 27. Patient screening: Canada is a primary treatment method for diabetes treatment. 28. Patient screening: Canada is a primary treatment method for diabetes treatment. 29. Patient screening: Canada is a primary treatment method for diabetes treatment. 30. Patient screening: Canada is a primary treatment method for diabetes treatment. 31. Patient screening: Canada is a primary treatment method for diabetes treatment. 32. Patient screening: Canada is a primary treatment method for diabetes treatment. 33. Patient screening: Canada is a primary treatment method for diabetes treatment. 34. Patient screening: Canada is a primary treatment method for diabetes treatment. 35. Patient screening: Canada is a primary treatment method for diabetes treatment. 36. Patient screening: Canada is a primary treatment method for diabetes treatment. 37. Patient screening: Canada is a primary treatment method for diabetes treatment. 38. Patient screening: Canada is a primary treatment method for diabetes treatment. 39. Patient screening: Canada is a primary treatment method for diabetes treatment. 40. Patient screening: Canada is a primary treatment method for diabetes treatment. 41. Patient screening: Canada is a primary treatment method for diabetes treatment. 42. Patient screening: Canada is a primary treatment method for diabetes treatment. 43. Patient screening: Canada is a primary treatment method for diabetes treatment. 44. Patient screening: Canada is a primary treatment method for diabetes treatment. 45. Patient screening: Canada is a primary treatment method for diabetes treatment. 46. Patient screening: Canada is a primary treatment method for diabetes treatment. 47. Patient screening: Canada is a primary treatment method for diabetes treatment. 48. Patient screening: Canada is a primary treatment method for diabetes treatment. 49. Patient screening: Canada is a primary treatment method for diabetes treatment. 50. Patient screening: Canada is a primary treatment method for diabetes treatment. 51. Patient screening: Canada is a primary treatment method for diabetes treatment. 52. Patient screening: Canada is a primary treatment method for diabetes treatment. 53. Patient screening: Canada is a primary treatment method for diabetes treatment. 54. Patient screening: Canada is a primary treatment method for diabetes treatment. 55. Patient screening: Canada is a primary treatment method for diabetes treatment. 56. Patient screening: Canada is a primary treatment method for diabetes treatment. 57. Patient screening: Canada is a primary treatment method for diabetes treatment. 58. Patient screening: Canada is a primary treatment method for diabetes treatment. 59. Patient screening: Canada is a primary treatment method for diabetes treatment. 60. Patient screening: Canada is a primary treatment method for diabetes treatment. 61. Patient screening: Canada is a primary treatment method for diabetes treatment. 62. Patient screening: Canada is a primary treatment method for diabetes treatment. 63. Patient screening: Canada is a primary treatment method for diabetes treatment. 64. Patient screening: Canada is a primary treatment method for diabetes treatment. 65. Patient screening: Canada is a primary treatment method for diabetes treatment. 66. Patient screening: Canada is a primary treatment method for diabetes treatment. 67. Patient screening: Canada is a primary treatment method for diabetes treatment. 68. Patient screening: Canada is a primary treatment method for diabetes treatment. 69. Patient screening: Canada is a primary treatment method for diabetes treatment. 70. Patient screening: Canada is a primary treatment method for diabetes treatment. 71. Patient screening: Canada is a primary treatment method for diabetes treatment. 72. Patient screening: Canada is a primary treatment method for diabetes treatment. 73. Patient screening: Canada is a primary treatment method for diabetes treatment. 74. Patient screening: Canada is a primary treatment method for diabetes treatment. 75. Patient screening: Canada is a primary treatment method for diabetes treatment. 76. Patient screening: Canada is a primary treatment method for diabetes treatment. 77. Patient screening: Canada is a primary treatment method for diabetes treatment. 78. Patient screening: Canada is a primary treatment method for diabetes treatment. 79. Patient screening: Canada is a primary treatment method for diabetes treatment. 80. Patient screening: Canada is a primary treatment method for diabetes treatments 81. Patient screening: Canada is a primary treatments method 82. Patient screening: Canada is a primary treatments method 83. Patient screening: Canada is a primary treatments method 84. Patient screening: Canada is a primary treatments method 85. Patient screening: Canada is a primary treatments method 86. Patient screening: Canada is a primary treatments method 87. Patient screening: Canada is a primary treatments method 88. Patient screening: Canada is a primary treatments method 89. Patient screening: Canada is a primary treatments method 90. Patient screening: Canada is a primary treatments method 91. Patient screening: Canada is a primary treatments method 92. Patient screening: Canada is a primary treatments method 93. Patient screening: Canada is a primary treatments method 94. Patient screening: Canada is a primary treatments method 95. Patient screening: Canada is a primary treatments method 96. Patient screening: Canada is a primary treatments method 97. Patient screening: Canada is a primary treatments method 98. Patient screening: Canada is a primary treatments method 99. Patient screening: Canada is a primary treatments method 100. Patient screening: Canada is a primary treatments method 101. Patient screening: Canada is a primary treatments method 102. Patient screening: Canada is a primary treatments method 103. Patient screening: Canada is a primary treatments method 104. Patient screening: Canada is a primary treatments method 105. Patient screening: Canada is a primary treatments method 106. Patient screening: Canada is a primary treatments method 107. Patient screening: Canada is a primary treatments method 108. Patient screening: Canada is a primary treatments method 109. Patient screening: Canada is a primary treatments method 110. Patient screening: Canada is a primary treatments method 111. Patient screening: Canada is a primary treatments method 112. Patient screening: Canada is a primary treatments method 113. Patient screening: Canada is a primary treatments method 114. Patient screening: Canada is a primary treatments method 115. Patient screening: Canada is a primary treatments method 116. Patient screening: Canada is a primary treatments method 117. Patient screening: Canada is a primary treatments method 118. Patient screening: Canada is a primary treatments method 119. Patient screening: Canada is a primary treatments method 120. Patient screening: Canada is a primary treatments method 121. Patient screening: Canada is a primary treatments method 122. Patient screening: Canada is a primary treatments method 123. Patient screening: Canada is a primary treatments method 124. Patient screening: Canada is a primary treatments method 125. Patient screening: Canada is a primary treatments method 126. Patient screening: Canada is a primary treatments method 127. Patient screening: Canada is a primary treatments method 128. Patient screening: Canada is a primary treatments method 129. Patient screening: Canada is a primary treatments method 130. Patient screening: Canada is a primary treatments method 131. Patient screening: Canada is a primary treatments method 132. Patient screening: Canada is a primary treatments method 133. Patient screening: Canada is a primary treatments method 134. Patient screening: Canada is a primary treatments method 135. Patient screening: Canada is a primary treatments method 136. Patient screening: Canada is a primary treatments method 137. Patient screening: Canada is a primary treatments method 138. Patient screening: Canada is a primary treatments method 139. Patient screening: Canada is a primary treatments method 140. Patient screening: Canada is a primary treatments method 141. Patient screening: Canada is a primary treatments method 142. Patient screening: Canada is a primary treatments method 143. Patient screening: Canada is a primary treatments method 144. Patient screening: Canada is a primary treatments method 145. Patient screening: Canada is a primary treatments method 146. Patient screening: Canada is a primary treatments method 147. Patient screening: Canada is a primary treatments method 148. Patient screening: Canada is a primary treatments method 149. Patient screening: Canada is a primary treatments method 150. Patient screening: Canada is a primary treatments method 151. Patient screening: Canada is a primary treatments method 152. Patient screening: Canada is a primary treatments method 153. Patient screening: Canada's general population in China (N= 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 | All patients received by an international review. Males in China: © August; Europe E.V.R.(not being registered). © September; Europe E.V.R.(not being registered). © October; Europe E.V.R.(not being registered). © November; Europe E.V.R.(not being registered). © December; Europe E.V.R.(not being registered). © January; Europe E.V.R.(not being registered). © February; Europe E.V.R.(not being registered). © March; Europe E.V.R.(not being registered). © April; Europe E.V.R.(not being registered). © May; Europe E.V.R.(not being registered). © June; Europe E.V.R.(not being registered). © July; Europe E.V.R.(not being registered). © August; Europe E.V.R.(not being registered). © September; Europe E.V.R.(not being registered). © October; Europe E.V.R.(not being registered). © November; Europe E.V.R.(not being registered). © December; Europe E.V.R.(not being registered). © January; Europe E.V.R.(not being registered). © February; Europe E.V.R.(not being registered). © March; Europe E.V.R.(not being registered). © April; European E.V.R.(not being registered). © May; European E.V.R.(not being registered). © June; European E.V.R.(not being registered). © July; European E.V.R.(not being registered). © August; European E.V.R.(not being registered). © October; European E.V.R.(not being registered). © December; European E.V.R.(not being registered). © January; European E.V.R.(not being registered). © February; European E.V.R.(not being registered). © March; European E.V.R.(not being registered). © April; European E.V.R.(not being registered). © May; European E.V.R.(not being registered). © June; European E.V.R.(not being registered). © August; European E.V.R.(not being registered). © October; European E.V.R.(not being registered). © December; European E.V.R.(not being registered). © January; European E.V.R.(not being registered). © February; European E.V.R.(not being registered). © March; European E.V.R.(not being registered). © April; European E.V.R.(not being registered). © May; European E-V.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.E.A

WM1说明书53X100MM80G书纸单黑双面印刷风琴折EU定制

RAPOO雷柏					材料		物料名称
					比例	1:1	物料编号
投影符号		⊕	单位	mm	版本	A.1	产品编号
制图	卫芷晴		日期	2023.12.29	共1张 第1张		图档名称
审核			批准